Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
about
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host diseaseThe effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysisVisualization and communication of pharmacometric models with berkeley madonnaOseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyAmyotrophic lateral sclerosis disease progression model.Analysis of population pharmacokinetic data using NONMEM and WinBUGS.Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions.Evaluation of estimation, prediction and inference for autocorrelated latent variable modeling of binary data-a simulation study.The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data.An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical dataRomiplostim dose response in patients with immune thrombocytopenia.Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China.Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightPopulation Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.Tips and traps analyzing pediatric PK data.Estimating transformations for repeated measures modeling of continuous bounded outcome data.Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureAutomatic data binning for improved visual diagnosis of pharmacometric models.Immunogenicity of panitumumab in combination chemotherapy clinical trialsCharacterization of the time course of carbamazepine deinduction by an enzyme turnover modelPharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosisExtension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.Genome-wide interrogation of longitudinal FEV1 in children with asthmaPharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosisMechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjectsExposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.A prospective population pharmacokinetic analysis of sapropterin dihydrochloride in infants and young children with phenylketonuria.Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancyPharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjectsRifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
P2860
Q28299731-B67522B6-D19C-43F2-8D75-C169790E9AAAQ28472672-C9456D35-045E-474E-BB55-66CD153FB6BDQ29584444-890C95FA-97E4-4DD3-8A19-70134F2DEB2CQ30407250-A8B712DB-D58C-4C43-93B3-A824D20E7CE6Q30443910-70C245B4-C554-4A48-8293-5B76CEF1B437Q30486384-231B4F7E-A51D-44D8-9FEE-60EC50E8E5B5Q30982415-5FA8B5FB-702B-47D2-8E55-4E94D8C16B5CQ31020563-236BE358-BCB5-44AE-A185-D6301544F8DEQ31061993-803A3AF6-B8D6-4FBE-9454-B8A7D1F488EAQ31127244-EDFE39BC-D582-4A3A-8551-9A53296DD430Q31131623-E3C65B12-AD7C-4F84-81EF-4B0BBE00B469Q33212737-E0D9FFF4-DD38-4016-B45C-74B71D346611Q33398730-37F294E9-52C7-4ED2-94E9-AD2818A42B9FQ33553063-B0D663D4-ED49-49C7-B4D3-478980D17D57Q33571412-14C3DBA6-E03D-4EB7-9EED-098EDD1D20CAQ33729774-4327A823-9B11-427C-8F05-39CC85FE6E83Q33729811-83068244-6633-4623-9B69-839E892A753CQ33764995-09144CF7-9C1E-4E7B-9DA8-EA733594CC9AQ33820152-BB675B45-D69F-435E-B7FD-C2751FA8DC71Q33864905-E55BCCFB-969F-4B6A-805D-448EDFB98B13Q34055606-E2976782-08BC-48C5-AF53-F3B4E9520FB4Q34063375-62F3CFB8-D511-41F6-B837-FFF0411A0204Q34070944-A016B6EC-2AAC-425C-AE6E-7C541CAABA41Q34156256-DA67DD73-349B-47F4-9DC0-E88089742351Q34300500-67021DB4-BD3F-4CC5-95AF-37A4230FA17CQ34376951-DA941788-9749-4BB0-9486-FDE3E7305747Q34425888-EE397527-D091-47A5-9CC6-D6FAF9F0AA72Q34544598-B50E999D-6EFA-45BF-A122-7EEE88AC9294Q34580659-E4D0C8CD-5ABF-45F0-970B-334F860CB0A0Q34589338-8727ECAA-8014-4E61-B52F-6287DB296482Q34635575-999D1ED2-8514-4872-96EF-FFE4442EE434Q35004269-57D1A3F9-532D-4422-B91E-571BF19D3BCBQ35012215-0CDE7DBD-3032-4691-B229-66B26CFE4728Q35025745-112E4B23-D367-4B56-A089-86868362A1A7Q35132886-1EA76E0F-F206-473E-9CD5-7DAE56AAB2B5Q35167188-42D3B69E-7D6F-4962-B888-1237618F2E83Q35318113-FED48F89-24E4-4924-866C-C198CD39F7A4Q35557435-760E5EB1-2D4E-48E3-BBB9-1B4677803913Q35595776-06B222AE-B55B-4041-BC4D-E68D85661F62Q35598523-0D959D54-D886-4507-8A8E-DD94478D1857
P2860
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@en
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@nl
type
label
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@en
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@nl
prefLabel
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@en
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@nl
P2093
P356
P1476
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
@en
P2093
P2888
P304
P356
10.1023/A:1011555016423
P577
2001-04-01T00:00:00Z
P6179
1032175473